David F. M. Brown, MD
President, Mass General
Executive Vice President, Mass General Brigham
David F. M. Brown, MD is President of Massachusetts General Hospital, Executive Vice President of Mass General Brigham, and the Mass General Trustees Professor of Emergency Medicine at Harvard Medical School.
Prior to becoming President of Mass General, Dr. Brown served as Chair of the Department of Emergency Medicine at Massachusetts General Hospital from 2013 to 2021 and as interim President and CEO of Cooley Dickinson Health Care in 2021.
Dr. Brown is a Phi Beta Kappa graduate of Princeton University and received his MD from Columbia University College of Physicians & Surgeons, where he was a member of Alpha Omega Alpha. He trained at Massachusetts General Hospital and is a diplomate of both the American Board of Emergency Medicine and the American Board of Internal Medicine. He is a fellow of the American College of Emergency Physicians and the American Academy of Emergency Medicine.
An accomplished clinician, scholar, teacher, mentor and administrator, Dr. Brown is the author of more than 250 peer-reviewed articles, reviews, and chapters, has written two popular textbooks related to cardiovascular emergencies, and served as the inaugural editor-in-chief of the textbook Scientific American: Emergency Medicine. He has been recognized by trainees and peers with multiple local, national, and international teaching and mentorship awards.
Merit E. Cudkowicz, MD, MSC
Director, Sean M. Healey & AMG Center for ALS
Chief, Neurology Department, Mass General
Julieanne Dorn Professor of Neurology, Harvard Medical School
Dr. Merit Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chief of Neurology at Mass General, Director and the Julieanne Dorn Professor of Neurology at Harvard Medical School. Dr. Cudkowicz’s research and clinical activities are dedicated to the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS). Dr. Cudkowicz is one of the founders and past Co-Chairs of the Northeast ALS Consortium (NEALS), a group of over 134 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative clinical trials and research in ALS. She has brought innovations to accelerate the development of treatments for people with ALS, including senior role in first antisense oligonucleotide treatment for a neurological disorder (SOD1 ALS), adaptive trial designs, central IRB – all with goal to bring the best treatments rapidly. Dr. Cudkowicz is Principal Investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke’s Neurology Network of Excellence in Clinical Trials (NeuroNEXT). Dr. Cudkowicz is launching the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that will greatly accelerate therapy development in ALS.
Dr. Cudkowicz received the American Academy of Neurology 2009 Sheila Essay ALS award, the 2017 Forbes Norris Award from the International MND Alliance, the 2017 Pinnacle Award from the Boston Chamber of Commerce and the 2019 Ray Adams American Neurological Association Award. A dedicated educator, Dr. Cudkowicz mentors many young neurologists in clinical investigation of ALS and related neurodegenerative disorders. Dr. Cudkowicz completed her undergraduate degree in chemical engineering at Massachusetts Institute of Technology and obtained a medical degree in the Health Science and Technology program of Harvard Medical School. She served her internship at Beth Israel Hospital in New York and her neurology residency and fellowship at MGH. She also obtained a master’s degree in Clinical Epidemiology from the Harvard School of Public Health.